We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Cancer Immunotherapy Sector Predicted to Surge to USD 9 Billion Across Major Pharma Through 2022

By LabMedica International staff writers
Posted on 30 Jul 2014
Print article
The immunotherapy market will experience substantial growth through 2022, increasing from USD 1.1 billion in 2012 to nearly USD 9 billion in 2022 (corresponding to 23.8% annual growth) in the United Kingdom, United States, France, Germany, Italy, Spain, and Japan, according to recent market research.

This notable growth will be fueled by the anticipated market entry of nine novel immunotherapies--including four novel immune checkpoint inhibitors and five novel therapeutic vaccines—in new oncology indications and/or patient populations, according to Decision Resources Group (Burlington, MA, USA). Combined, Bristol-Myers Squibb’s anti-CTLA-4 agent Yervoy and innovative immune checkpoint inhibitors that target the anti-programmed cell death-1/programmed death-ligand-1 (PD-1/PD-L1) pathway—including Bristol-Myers Squibb/Ono Pharmaceutical’s nivolumab, Merck & Co.'s pembrolizumab (MK-3475), Roche/Genentech/Chugai’s MPDL-3280A and AstraZeneca/MedImmune’s MEDI4736—should dominate the immunotherapy market and capture a remarkable 85% market share in 2022.

Other key findings from the Pharmacor Immunotherapies advisory service include: potential of anti-PD-1/PD-L1 agents: Interviewed experts are considerably excited about the potential of anti-PD-1/PD-L1 agents based on encouraging data released to date in multiple oncology indications. The added prospect of using PD-L1 expression as a potential predictive biomarker for customizing treatment fascinated interviewed experts; however, they remain watchful on this point, noting that considerable heterogeneity exists in PD-L1 expression and that good objective responses have also been reported in patients considered to have no or low levels of PD-L1 expression.

Because of the impressive early-phase data presented at the 2014 annual meeting of the American Society for Clinical Oncology (ASCO), held May 30-June 3, 2014, in Chicago (IL, USA), interviewed experts expressed enthusiasm for combination approaches involving immunotherapies—including dual blockade of the immune checkpoint pathway, combinations of immune checkpoint inhibitors with therapeutic cancer vaccines and combinations of immune checkpoint inhibitors with chemotherapy.

The therapeutic vaccines segment will see, according to Decision Resources Group, 13.6% annual sales growth over the 2012 to 2022 forecast period, although, with combined major-market sales reaching USD 1.2 billion in 2022, these agents will not reach the commercial success of immune checkpoint inhibitors.

Decision Resources Group senior business insights analyst Khurram Nawaz, MSc, commented, “A plethora of immunotherapies are in development across a wide range of oncology indications, making this drug class one of the most exciting to watch. We anticipate that nivolumab will be the sales-leading agent among immunotherapies. However, it will face direct and intense competition from other anti-PD-1/PD-L1 agents—notably from pembrolizumab in malignant melanoma and non-small-cell lung cancer—and to a lesser degree, from MPDL-3280A in non-small-cell lung cancer. Interviewed experts express mixed reactions to therapeutic vaccines and note the challenges in monitoring the efficacy of these agents. Nevertheless, they are hopeful that some vaccines will provide new therapeutic options and hold greatest promise as part of combination strategies.”

Decision Resources Group offers information and insights on critical issues within the healthcare industry.

Related Links:

Decision Resources Group


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
HLX
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Xylazine Immunoassay Test
Xylazine ELISA

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Molecular Diagnostics

view channel
Image: MOF materials efficiently enrich cfDNA and cfRNA in blood through simple operational process (Photo courtesy of Science China Press)

Blood Circulating Nucleic Acid Enrichment Technique Enables Non-Invasive Liver Cancer Diagnosis

The ability to diagnose diseases early can significantly enhance the effectiveness of clinical treatments and improve survival rates. One promising approach for non-invasive early diagnosis is the use... Read more

Hematology

view channel
Image: The low-cost portable device rapidly identifies chemotherapy patients at risk of sepsis (Photo courtesy of 52North Health)

POC Finger-Prick Blood Test Determines Risk of Neutropenic Sepsis in Patients Undergoing Chemotherapy

Neutropenia, a decrease in neutrophils (a type of white blood cell crucial for fighting infections), is a frequent side effect of certain cancer treatments. This condition elevates the risk of infections,... Read more

Pathology

view channel
Image: The OvaCis Rapid Test discriminates benign from malignant epithelial ovarian cysts (Photo courtesy of INEX)

Intra-Operative POC Device Distinguishes Between Benign and Malignant Ovarian Cysts within 15 Minutes

Ovarian cysts represent a significant health issue for women globally, with up to 10% experiencing this condition at some point in their lives. These cysts form when fluid collects within a thin membrane... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.